Multicenter Open-label Randomized, Comparative Clinical Study to Evaluate Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b, CJSC "BIOCAD", Russia) With Ribavirin Compared to PegIntron (Peginterferon Alfa-2b, Schering-Plough Labo N.V., Belgium) With Ribavirin in Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
Phase of Trial: Phase III
Latest Information Update: 20 Aug 2018
Price : $35 *
At a glance
- Drugs Cepeginterferon alfa 2b (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Biocad
- 31 Aug 2018 Biomarkers information updated
- 13 Jul 2018 Status changed from active, no longer recruiting to completed.
- 12 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016, as reported by ClinicalTrials.gov record.